Relative Bioavailability Study to Investigate a Potential Interaction Between DTG DT and F/TAF TOS.
NCT05489406
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
16
Enrollment
OTHER
Sponsor class
Conditions
Hiv
Interventions
DRUG:
DTG DT (6 x 5 mg)
DRUG:
F/TAF TOS (3 x 60/7.5 mg)
Sponsor
Radboud University Medical Center
Collaborators
[object Object]